Ardelyx, Inc. (ARDX): Price and Financial Metrics


Ardelyx, Inc. (ARDX): $0.61

0.01 (+1.75%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ARDX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ARDX POWR Grades


  • Value is the dimension where ARDX ranks best; there it ranks ahead of 52.59% of US stocks.
  • The strongest trend for ARDX is in Momentum, which has been heading down over the past 179 days.
  • ARDX's current lowest rank is in the Stability metric (where it is better than 2.89% of US stocks).

ARDX Stock Summary

  • With a price/sales ratio of 13.81, Ardelyx Inc has a higher such ratio than 89.51% of stocks in our set.
  • The volatility of Ardelyx Inc's share price is greater than that of 99.88% US stocks with at least 200 days of trading history.
  • Ardelyx Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -59.61%, greater than the shareholder yield of only 7.37% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Ardelyx Inc are CLVS, SMCI, FBIO, TVTX, and APM.
  • Visit ARDX's SEC page to see the company's official filings. To visit the company's web site, go to www.ardelyx.com.

ARDX Valuation Summary

  • In comparison to the median Healthcare stock, ARDX's EV/EBIT ratio is 103.41% lower, now standing at -1.
  • ARDX's EV/EBIT ratio has moved up 31.4 over the prior 88 months.
  • Over the past 88 months, ARDX's price/earnings ratio has gone up 35.8.

Below are key valuation metrics over time for ARDX.

Stock Date P/S P/B P/E EV/EBIT
ARDX 2021-08-31 11.7 1.2 -1.2 -1.0
ARDX 2021-08-30 12.0 1.3 -1.2 -1.1
ARDX 2021-08-27 12.0 1.3 -1.2 -1.1
ARDX 2021-08-26 12.0 1.3 -1.2 -1.1
ARDX 2021-08-25 11.6 1.2 -1.2 -1.0
ARDX 2021-08-24 12.2 1.3 -1.2 -1.1

ARDX Growth Metrics

    The 3 year net cashflow from operations growth rate now stands at -0.63%.
  • Its 2 year price growth rate is now at 42.77%.
  • Its year over year price growth rate is now at -8.18%.
ARDX's revenue has moved down $8,046,000 over the prior 70 months.

The table below shows ARDX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 10.097 -152.551 -158.165
2021-09-30 10.877 -130.672 -150.807
2021-06-30 12.417 -115.96 -125.328
2021-03-31 12.94 -100.706 -105.095
2020-12-31 7.571 -81.435 -94.313
2020-09-30 8.012 -74.982 -85.227

ARDX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ARDX has a Quality Grade of C, ranking ahead of 26.73% of graded US stocks.
  • ARDX's asset turnover comes in at 0.061 -- ranking 306th of 682 Pharmaceutical Products stocks.
  • XBIO, CBAY, and BPTH are the stocks whose asset turnover ratios are most correlated with ARDX.

The table below shows ARDX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.061 0.919 -0.887
2021-03-31 0.063 0.912 -0.724
2020-12-31 0.036 0.981 -0.618
2020-09-30 0.035 0.982 -0.579
2020-06-30 0.040 0.911 -0.719
2020-03-31 0.035 0.908 -0.806

ARDX Price Target

For more insight on analysts targets of ARDX, see our ARDX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.21 Average Broker Recommendation 1.62 (Moderate Buy)

ARDX Stock Price Chart Interactive Chart >

Price chart for ARDX

ARDX Price/Volume Stats

Current price $0.61 52-week high $2.15
Prev. close $0.60 52-week low $0.58
Day low $0.59 Volume 1,111,367
Day high $0.62 Avg. volume 3,322,313
50-day MA $0.88 Dividend yield N/A
200-day MA $1.06 Market Cap 87.54M

Ardelyx, Inc. (ARDX) Company Bio


Ardelyx is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative, minimally-systemic, small molecule therapeutics that work exclusively in the gastrointestinal tract to treat cardio-renal, gastrointestinal and metabolic diseases. The company was founded in 2007 and is based in Fremont, California.


ARDX Latest News Stream


Event/Time News Detail
Loading, please wait...

ARDX Latest Social Stream


Loading social stream, please wait...

View Full ARDX Social Stream

Latest ARDX News From Around the Web

Below are the latest news stories about Ardelyx Inc that investors may wish to consider to help them evaluate ARDX as an investment opportunity.

Aerie Pharmaceuticals (AERI) Tops Q4 Earnings and Revenue Estimates

Aerie (AERI) delivered earnings and revenue surprises of 260.29% and 272.10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

Ardelyx Announces $27.5 Million Debt Financing Agreement with SLR Capital Partners

Ardelyx, Inc. (Nasdaq:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that it has entered into a debt financing agreement with investment affiliates managed by SLR Capital Partners ("SLR").

Yahoo | February 24, 2022

Ardelyx to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that it will hold a conference call on Monday February 28, at 4:30 pm Eastern Time to discuss fourth quarter and year-end 2021 financial results and provide a corporate update.

Yahoo | February 22, 2022

Ardelyx, Inc. Reports Employment Inducement Grants

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that on February 1, 2022, the compensation committee of the company's board of directors granted four new non-executive employees options to purchase an aggregate of 35,547 shares of the company's common stock, and granted an aggregate of 25,750 Restricted Stock Units (RSUs) to five n

Yahoo | February 4, 2022

Clarius Group, LLC Buys BTC BlackRock Ultra Short-Term Bond ETF, , Vanguard Ultra-Short Bond ...

Investment company Clarius Group, LLC (Current Portfolio) buys BTC BlackRock Ultra Short-Term Bond ETF, , Vanguard Ultra-Short Bond ETF, Vanguard FTSE Emerging Markets ETF, iShares Core U.S.

Yahoo | February 2, 2022

Read More 'ARDX' Stories Here

ARDX Price Returns

1-mo -38.13%
3-mo -13.96%
6-mo -31.65%
1-year -64.94%
3-year -13.17%
5-year -46.96%
YTD -44.55%
2021 -31.99%
2020 -13.79%
2019 319.28%
2018 -72.88%
2017 -53.52%

Continue Researching ARDX

Here are a few links from around the web to help you further your research on Ardelyx Inc's stock as an investment opportunity:

Ardelyx Inc (ARDX) Stock Price | Nasdaq
Ardelyx Inc (ARDX) Stock Quote, History and News - Yahoo Finance
Ardelyx Inc (ARDX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9657 seconds.